SEC Filing Summary

This filing details a transaction by Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. On April 17, 2026, Miller disposed of 558 shares of Common Stock at a price of $1.78 per share. This transaction was made to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units. Following this transaction, Miller owns 33,121 shares of Acrivon Therapeutics, Inc. common stock. The filing is Form 4, indicating a change in beneficial ownership.